Taiwan's biotechnology industry is poised to cash in on drugs developed from traditional Chinese herbal remedies, experts said yesterday.
"In Taiwan, we are doing good research in Chinese herbal rem-edies, but now we need to commercialize," Winston Town (湯竣鈞), chief operating officer of herbal drug developer Cathay Biotech Co (中華公明生物科技), told the Taipei Times yesterday.
In order to turn research investments into big bucks, companies have to prove scientifically that Chinese herbal remedies work, and the only way to do that is to present them for approval to regulatory authorities in the US, Europe and Japan, Town said.
Taiwan is banking on biotechnology and other advanced industries to replace manufacturing that has now moved to low-cost China.
In May of last year, President Chen Shui-bian (
Exploiting the nation's cultural heritage could help biotech companies to produce their own uniquely Chinese drugs.
"Traditional Chinese medicine offers excellent opportunities for Taiwanese biotechnology companies," said Jerry Chen (
Only last Friday Chen's office hosted a business opportunities forum for companies interested in developing drugs from Chinese herbs, and over 100 people attended, Chen said.
The government has funded three research centers to look specifically at herb-based drugs, the Development Center for Biotechnology in Taipei, the Pharmaceutical Industry Technology and Development Center in Taipei County and the Biomedical Engineering Center at the Industrial Technology Research Institute in Hsinchu.
But research is not enough.
"There is a huge amount of potential for Taiwanese companies through herbal medicine," said David Silver, director of Biotech-east.com, a Web site that promotes Taiwan's biotechnology and pharmaceutical industries. "But there are problems with patentability and regulations."
Companies cannot claim a patent on naturally occurring plants, but they can patent an effective chemical compound extracted from a plant that they have isolated, or present a mixture of herbs to regulatory authorities in the US, Europe and Japan and ask for approval.
To do this, they need to have carried out quality control tests and be able to guarantee consistent dosages, Silver said.
Isolating one compound in an herb is a very difficult process that involves a lot of computing power and time, Silver said, but it is very lucrative if successful. Presenting an herbal mix for approval is much simpler, and is now possible after US Food and Drug Administration rules were changed last year.
That is exactly what Cathay is doing with a mixture of 15 different Chinese herbs that it claims from its own preliminary trials can treat sufferers of Hepatitis B and HIV.
On the strength of this research, Cathay submitted an application to the FDA for its multi-herb treatment and had it accepted, Town said yesterday.
Town expects the second phase of clinical trials to be completed and approved within 12 months. After that, Cathay can sell licenses for its treatment to global pharmaceutical companies who have the resources to complete the third and final phase of trials before marketing the drug globally.
Other Taiwanese companies could follow this route.
"Our business model works," Cathay's chairman, David Wu (
While awaiting FDA approval Cathay is exploring other avenues, Wu added. In Taiwan, Cathay's approved over-the-counter liver tonic, called YGK (
If successful, the drug would be paid for by international humanitarian donations.
HEAVY INVESTMENT: Moody’s affirmed the firm’s ‘Aa3’ rating with a ‘stable’ outlook due to its leading position in the industry and ability to match customer requirements Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) revenue this year is expected to increase about 21 percent to NT$1.29 trillion (US$44.01 billion) from NT$1.07 trillion last year, driven by strong demand for advanced 5-nanometer and 7-nanometer chips mainly used in smartphones and high-performance computing devices, a Moody’s Investors Service report on Wednesday said. TSMC’s rate of revenue growth next year is to increase to 7.5 percent, the ratings agency said. The company, which supplies 5-nanometer chips for Apple Inc’s new iPad series, has introduced the advanced chips ahead of its competitors and gained a significant share of the market for the foundry industry’s
NO VIRUS BLUES: A SEMI Taiwan official said that the virus does not slow down the global semiconductor industry’s investment in manufacturing equipment The production value of the nation’s semiconductor industry is expected to grow 16.7 percent this year from last year, outpacing the global industry’s 3.3 percent growth, industry association SEMI said yesterday. That would help Taiwan safeguard its second spot in the global semiconductor market with a production value of more than NT$3 trillion (US$102.73 billion), SEMI Taiwan president Terry Tsao (曹世綸) told a media briefing in Taipei for the Semicon Taiwan trade show beginning today. The global semiconductor industry’s production value is expected to increase to US$426 billion this year, SEMI said. In terms of semiconductor equipment investment, equipment billings from Taiwanese firms
Intel Corp has received licenses from US authorities to continue supplying certain products to Huawei Technologies Co (華為), a company spokesman said yesterday. Washington has been pushing governments around to world to squeeze out Huawei, saying that the telecom giant would hand data to Beijing for espionage. From Monday last week, new curbs have barred US companies from supplying or servicing Huawei. This week, the state-backed China Securities Journal reported that Intel had received permission to supply Huawei. China’s Semiconductor Manufacturing International Corp (SMIC, 中芯國際), which uses US-origin equipment to make chips for Huawei and other companies, last week confirmed that it had sought
Taipei Times: When do you think the hospitality industry can return to how it was before the COVID-19 pandemic? How does Formosa International Hotels Group (FIH, 晶華酒店集團) fare this quarter and beyond? FIH chairman Steve Pan (潘思亮): The virus outbreak will have a serious impact on business travel, driven mainly by meetings, incentive travel, conferences and exhibitions over the past three decades. For the past six months, many businesspeople have grown used to exchanging information on the Internet, where more people can participate. The trend might sustain for three to five years until people are vaccinated and it is safe to